Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:

• Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer
• Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer
• Outcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs 

Program faculty:

Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts 

Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, Georgia

Resources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.